Real-world data of tirzepatide in obesity management: a multicenter study by the Italian Society of Obesity - Campania Region.

Renal function, assessed by eGFR, improved significantly from baseline with both doses (from 83.2 ± 13.2 to 84.6 ± 12.0 ml/min/1.73 m2 at 2.5 mg, p = 0.025, and to 85.6 ± 11.6 ml/min/1.73 m2 at 5.0 mg, p = 0.005); however, the difference between tirzepatide 2.5 mg and 5 mg did not reach statistical significance, although a trend toward greater improvement with the higher dose was observed (Figure 3 (Fig. 3) ).

also in 111,027 other papers

Renal function, assessed by eGFR, showed a trend toward improvement, which is encouraging in a population at increased risk for chronic kidney disease due to metabolic comorbidities.

also in 53,322 other papers